Compare MATH & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | ATNM |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | Hong Kong | United States |
| Employees | N/A | 31 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 47.1M |
| IPO Year | N/A | N/A |
| Metric | MATH | ATNM |
|---|---|---|
| Price | $2.51 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 102.0K | ★ 224.5K |
| Earning Date | 12-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $44,567,257.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $42,943.57 |
| P/E Ratio | $6.56 | ★ N/A |
| Revenue Growth | ★ 165.86 | 11.11 |
| 52 Week Low | $0.99 | $1.03 |
| 52 Week High | $4.17 | $2.41 |
| Indicator | MATH | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 57.56 |
| Support Level | $2.84 | $1.37 |
| Resistance Level | $3.04 | $1.69 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 4.48 | 52.78 |
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.